Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Jn7w3m3oi7
2. Vitamin A Acetate C20-d3
| Molecular Weight | 331.5 g/mol |
|---|---|
| Molecular Formula | C22H32O2 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 7 |
| Exact Mass | 331.259060497 g/mol |
| Monoisotopic Mass | 331.259060497 g/mol |
| Topological Polar Surface Area | 26.3 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 596 |
| Isotope Atom Count | 3 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 4 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Pharmaceuticals Reports Interim TEASE-3 Study Results for Stargardt
Details : ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2025
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Gets FDA Rare Pediatric and FTD for Gildeuretinol in Stargardt Disease
Details : ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2024
Details:
ALK-001 (gildeuretinol acetate) is a new chemical entity designed to reduce the dimerization of vitamin A without modulating the visual cycle in development for the treatment of GA secondary to AMD.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 23, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Shows Oral Gildeuretinol Slows GA Progression, Improves Visual Function
Details : ALK-001 (gildeuretinol acetate) is a new chemical entity designed to reduce the dimerization of vitamin A without modulating the visual cycle in development for the treatment of GA secondary to AMD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 23, 2024
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Geographic Atrophy.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Announces SAGA Study Results for Gildeuretinol in Geographic Atrophy
Details : ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Geographic Atrophy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2024
Details:
ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Pharmaceuticals Shows Progress in Stargardt Disease with TEASE-3 Study Update
Details : ALK-001 (gildeuretinol acetate) is a novel molecule created as a specialized form of deuterated vitamin A. It is under phase 2 clinical development for the treatment of Stargardt Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2024
Details:
ALK-001 (gildeuretinol acetate), a deuterated form of vitamin A, is in Phase 2 clinical trials for treating Stargardt Disease by reducing vitamin A dimerization without disrupting vision.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Reports Positive Results in Early-stage Stargardt Disease with Gildeuretinol
Details : ALK-001 (gildeuretinol acetate), a deuterated form of vitamin A, is in Phase 2 clinical trials for treating Stargardt Disease by reducing vitamin A dimerization without disrupting vision.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2024
Details:
ALK-001 (gildeuretinol acetate), a specialized deuterated vitamin A form, is under Phase 2 trials for Stargardt Disease by reducing vitamin A dimerization without impairing vision.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2024
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkeus Presents Interim Data Showing Gildeuretinol Halting Stargardt Disease Progression
Details : ALK-001 (gildeuretinol acetate), a specialized deuterated vitamin A form, is under Phase 2 trials for Stargardt Disease by reducing vitamin A dimerization without impairing vision.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2024
Details:
The financing will support the registration and launch of ALK-001 (gildeuretinol), a novel, specifically deuterated form of vitamin A and a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Bain Capital Life Sciences
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 05, 2023
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $150.0 million
Deal Type : Series B Financing
Details : The financing will support the registration and launch of ALK-001 (gildeuretinol), a novel, specifically deuterated form of vitamin A and a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 05, 2023
Details:
ALK-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stargardt Disease.
Lead Product(s): Gildeuretinol Acetate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2020
Lead Product(s) : Gildeuretinol Acetate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Details : ALK-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stargardt Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
67
PharmaCompass offers a list of Gildeuretinol Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gildeuretinol Acetate manufacturer or Gildeuretinol Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gildeuretinol Acetate manufacturer or Gildeuretinol Acetate supplier.
PharmaCompass also assists you with knowing the Gildeuretinol Acetate API Price utilized in the formulation of products. Gildeuretinol Acetate API Price is not always fixed or binding as the Gildeuretinol Acetate Price is obtained through a variety of data sources. The Gildeuretinol Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Gildeuretinol Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gildeuretinol Acetate, including repackagers and relabelers. The FDA regulates Gildeuretinol Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gildeuretinol Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gildeuretinol Acetate supplier is an individual or a company that provides Gildeuretinol Acetate active pharmaceutical ingredient (API) or Gildeuretinol Acetate finished formulations upon request. The Gildeuretinol Acetate suppliers may include Gildeuretinol Acetate API manufacturers, exporters, distributors and traders.
Gildeuretinol Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gildeuretinol Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gildeuretinol Acetate GMP manufacturer or Gildeuretinol Acetate GMP API supplier for your needs.
A Gildeuretinol Acetate CoA (Certificate of Analysis) is a formal document that attests to Gildeuretinol Acetate's compliance with Gildeuretinol Acetate specifications and serves as a tool for batch-level quality control.
Gildeuretinol Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Gildeuretinol Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gildeuretinol Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Gildeuretinol Acetate EP), Gildeuretinol Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gildeuretinol Acetate USP).
